SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ASMB

Assembly Biosciences, Inc. (NASDAQ:ASMB)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$22.19-$0.31 (-1.38%)
 
Market cap
$454M
Insider Score
Health Score
Analyst consensus
Listed since
Dec 17, 2010
Market Cap$454.39M-41.5%
Revenue (ttm)$67.01M+80.2%
Net Income-$11.10M+71.2%
EPS$0.82+115.1%
Shares Out20.48M
PE Ratio27.06
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume480,922
Open$22.22
Previous Close$22.50
Day's Range$21.98 - $22.78
52-Week Range$19.20 - $39.65
Beta1.22
AnalystsBuy
Price Target$51.67(+132.85%)
Earnings DateMar 18, 2027

About ASMB

Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.

Address
Two Tower Place, South San Francisco, CA, 94080, US
Market Cap
454 million
Employees
73
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$252.33K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $51.67 (+130.8%)

2 firms rating ASMB in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From ASMB’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-1.38%
5 Days
+5.07%
1 Month
+9.42%
6 Months
-21.70%
1 Year
-41.50%

$ASMB stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ASMB holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ASMB's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ASMB Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ASMB Revenue by Segment

$13.73MTotal
Less:$10.78M78.48%
Collaboration revenue from a related party$2.96M21.52%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ASMB patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ASMB from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ASMB

IWMiShares Russell 2000 ETF$7.99M
XBIState Street SPDR S&P Biotech ETF$6.96M
VTIVanguard Morningstar Total Stock Market ETF$6.79M
VXFVanguard Extended Market ETF$3.31M
IWNiShares Russell 2000 Value ETF$2.86M
VTWOVanguard Russell 2000 ETF$1.58M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ASMB’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
35

News check: Q3 earnings miss on revenue with reported loss indicates disappointing financial performance, though no major business disruptions or analyst downgrades noted.

Recent Insider Activity

Buys
0
Sells
13
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBCVirtus Biotech Clinical Trials ETF0.72%
IWCiShares Micro-Cap ETF0.07%
XBIState Street SPDR S&P Biotech ETF0.06%
PWSPacer WealthShield ETF0.01%
LABUDirexion Daily S&P Biotech Bull 3X Shares0.01%
VHTVanguard Health Care ETF0.00%

Weight is the stock’s share of each fund’s holdings.